Corbus Pharmaceuticals Holdings, Inc. - Common Stock, $0.0001 par value (CRBP)

Q: What does CUSIP 21833P301 represent in this 13F holders report?

CUSIP 21833P301 is the security identifier for CRBP - Corbus Pharmaceuticals Holdings, Inc. - Common Stock, $0.0001 par value used to aggregate holder disclosures.

Q: How many institutions held CRBP - Corbus Pharmaceuticals Holdings, Inc. - Common Stock, $0.0001 par value in Q2 2025?

78 institutional investors reported CRBP - Corbus Pharmaceuticals Holdings, Inc. - Common Stock, $0.0001 par value for Q2 2025. Use the holders table for investor-level position and value details.

CUSIP: 21833P301

Q2 2025 13F Holders as of 30 Jun 2025

Type / Class: Equity / Common Stock, $0.0001 par value
Shares outstanding: 17,685,185
Total 13F shares: 9,061,852
Share change: -1,367,126
Total reported value: $62,525,276
Put/Call ratio: 133%
Price per share: $6.90
Number of holders: 78
Value change: -$8,932,514
Number of buys: 29
Number of sells: 49

Quarterly Holders Quick Answers

What is CUSIP 21833P301?
CUSIP 21833P301 identifies CRBP - Corbus Pharmaceuticals Holdings, Inc. - Common Stock, $0.0001 par value in SEC institutional holdings data.

Need full ownership history?
Open the full security ownership history page.

Next holder-history checks

These links keep the next click tied to holder verification, nearby quarters, or outside-13F ownership context.

Back to full security ownership history for the broader multi-quarter picture.
Latest 13F filings for newly reported positions across managers.
Latest Schedule 13D/13G reports for ownership changes outside the 13F cadence.
SEC investors directory for manager drilldown.

Explore More Reporting Periods

Jump to adjacent filing periods for faster comparison and easier crawl discovery.

Newer quarter: Q3 2025
Previous quarter: Q1 2025

Recent filing periods for CUSIP 21833P301:

Q1 2026 Q4 2025 Q3 2025 Q2 2025 Q1 2025 Q4 2024 Q3 2024 Q2 2024

Top shareholders of CRBP - Corbus Pharmaceuticals Holdings, Inc. - Common Stock, $0.0001 par value (13F + 13D/G + 3/4/5)

Grouped by holder across the latest SEC ownership disclosures. Ownership % is shown only when it is directly reported or safely comparable across share classes.

Methodology: rows are grouped by holder and ranked by the holder's primary source value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.

Holder	Source	Role / Reporting	Ownership %	Shares	Holdings Value	12M Net Δ	As of	Details
Cormorant Asset Management, LP	13F	Company	13%	2,375,000	$12,611,250	—	31 Mar 2025	13F
Rachael Louise Brake	3/4/5	Chief Scientific Officer	— class O/S missing	1,400,000	$6,958,000	—	13 Feb 2023	3/4/5
ORBIMED ADVISORS LLC	13F 13D/G	Company · OrbiMed Capital LLC	5.9% from 13D/G	1,172,287	$6,224,844	—	31 Mar 2025	13F 13D/G
Octagon Capital Advisors LP	13F	Company	6.3%	1,115,000	$5,920,650	—	31 Mar 2025	13F
Craig Stuart Millian	3/4/5	Chief Operating Officer	— class O/S missing	934,645	$4,645,186	—	13 Feb 2023	3/4/5
BlackRock, Inc.	13F 13D/G	Company	2.9% from 13D/G	846,062	$4,492,588	—	31 Mar 2025	13F 13D/G
VANGUARD GROUP INC	13D/G 13F	The Vanguard Group · Company	4.9%	599,495	$4,136,516	$0	30 Jun 2025	13D/G 13F
Prosight Management, LP	13F	Company	3.3%	575,136	$3,053,972	—	31 Mar 2025	13F
RENAISSANCE TECHNOLOGIES LLC	13F	Company	2%	345,200	$1,833,012	—	31 Mar 2025	13F
Exome Asset Management LLC	13F	Company	1.6%	289,690	$1,538,255	—	31 Mar 2025	13F
GEODE CAPITAL MANAGEMENT, LLC	13F	Company	1.5%	271,514	$1,442,065	—	31 Mar 2025	13F
ARMISTICE CAPITAL, LLC	13F	Company	1.4%	250,000	$1,327,500	—	31 Mar 2025	13F
STATE STREET CORP	13F	Company	1.3%	223,470	$1,186,626	—	31 Mar 2025	13F
COMERICA BANK	13F	Company	1.1%	200,001	$1,062,005	—	31 Mar 2025	13F
ACADIAN ASSET MANAGEMENT LLC	13F	Company	1.1%	190,093	$1,007,000	—	31 Mar 2025	13F
MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd.	13F	Company	0.73%	129,043	$685,218	—	31 Mar 2025	13F
TANG CAPITAL MANAGEMENT LLC	13F	Company	0.72%	127,520	$677,131	—	31 Mar 2025	13F
TWO SIGMA INVESTMENTS, LP	13F	Company	0.69%	121,164	$643,381	—	31 Mar 2025	13F
AQR CAPITAL MANAGEMENT LLC	13F	Company	0.61%	107,983	$573,390	—	31 Mar 2025	13F
MILLENNIUM MANAGEMENT LLC	13F	Company	0.57%	101,607	$539,533	—	31 Mar 2025	13F
NORTHERN TRUST CORP	13F	Company	0.56%	99,883	$530,378	—	31 Mar 2025	13F
Atle Fund Management AB	13F	Company	0.56%	98,304	$521,994	—	31 Mar 2025	13F
CITADEL ADVISORS LLC	13F	Company	0.53%	92,991	$493,782	—	31 Mar 2025	13F
UBS Group AG	13F	Company	0.51%	90,844	$482,383	—	31 Mar 2025	13F
CHARLES SCHWAB INVESTMENT MANAGEMENT INC	13F	Company	0.5%	88,525	$470,068	—	31 Mar 2025	13F
PRELUDE CAPITAL MANAGEMENT, LLC	13F	Company	0.45%	80,347	$426,643	—	31 Mar 2025	13F
MORGAN STANLEY	13F	Company	0.43%	76,611	$406,804	—	31 Mar 2025	13F
HighVista Strategies LLC	13F	Company	0.43%	75,292	$399,801	—	31 Mar 2025	13F
Velan Capital Investment Management LP	13F	Company	0.33%	59,000	$313,290	—	31 Mar 2025	13F
GOLDMAN SACHS GROUP INC	13F	Company	0.33%	57,936	$307,641	—	31 Mar 2025	13F
AlphaQuest LLC	13F	Company	0.32%	56,390	$299,431	—	31 Mar 2025	13F
Alan F. Holmer	3/4/5	Director	— mixed-class rows	32,458 mixed-class rows	$254,268	—	30 May 2025	3/4/5
Nuveen, LLC	13F	Company	0.26%	45,689	$242,609	—	31 Mar 2025	13F
TWO SIGMA ADVISERS, LP	13F	Company	0.2%	36,140	$191,903	—	31 Mar 2025	13F
Stonepine Capital Management, LLC	13F	Company	0.2%	35,000	$185,850	—	31 Mar 2025	13F
SCHRODER INVESTMENT MANAGEMENT GROUP	13F	Company	0.18%	31,295	$172,748	—	31 Mar 2025	13F
Avery W. Catlin	3/4/5	Director	— mixed-class rows	7,133 mixed-class rows	$144,332	—	30 May 2024	3/4/5
Aberdeen Group plc	13F	Company	0.15%	26,894	$142,807	—	31 Mar 2025	13F
Rachelle Suzanne Jacques	3/4/5	Director	— mixed-class rows	26,366 mixed-class rows	$140,135	—	30 May 2025	3/4/5
Yong Ben	3/4/5	Director	— mixed-class rows	26,366 mixed-class rows	$140,135	—	30 May 2025	3/4/5
Bank of New York Mellon Corp	13F	Company	0.13%	23,206	$123,223	—	31 Mar 2025	13F
John Kenneth Jenkins	3/4/5	Director	— mixed-class rows	23,649 mixed-class rows	$120,582	-$20,465	30 May 2025	3/4/5
Verition Fund Management LLC	13F	Company	0.13%	22,485	$119,395	—	31 Mar 2025	13F
JANE STREET GROUP, LLC	13F	Company	0.12%	21,861	$116,082	—	31 Mar 2025	13F
Peter Salzmann	3/4/5	Director	— mixed-class rows	5,566 mixed-class rows	$97,322	—	30 May 2024	3/4/5
SUSQUEHANNA INTERNATIONAL GROUP, LLP	13F	Company	0.1%	18,218	$96,738	—	31 Mar 2025	13F
SEI INVESTMENTS CO	13F	Company	0.1%	17,589	$93,398	—	31 Mar 2025	13F
BANK OF AMERICA CORP /DE/	13F	Company	0.09%	16,579	$88,034	—	31 Mar 2025	13F
WEXFORD CAPITAL LP	13F	Company	0.09%	15,400	$81,770	—	31 Mar 2025	13F
RHUMBLINE ADVISERS	13F	Company	0.09%	15,139	$80,380	—	31 Mar 2025	13F

Institutional Holders of Corbus Pharmaceuticals Holdings, Inc. - Common Stock, $0.0001 par value (CRBP) as of Q2 2025

As of 30 Jun 2025, Corbus Pharmaceuticals Holdings, Inc. - Common Stock, $0.0001 par value (CRBP) was held by 78 institutional shareholders that filed Form 13F with the SEC. Together, they reported ownership of 9,061,852 shares. The largest 10 holders included Cormorant Asset Management, LP, ORBIMED ADVISORS LLC, Octagon Capital Advisors LP, VANGUARD GROUP INC, Prosight Management, LP, BlackRock, Inc., Exome Asset Management LLC, COMERICA BANK, ARMISTICE CAPITAL, LLC, and Atle Fund Management AB. This page lists 78 institutional shareholders reporting positions in this security for the Q2 2025 filing period.

Investor	Option	Weight %	Change %	Value $	* Price	Shares	Share Change	Activity	Report Period

Compare Q2 2025 vs Q1 2025 Across Filers

Q1 2025 holders

Q2 2025 holders

Holder diff

-7

Investor	Q1 2025 Shares	Q2 2025 Shares	Share Diff	Share Chg %	Q1 2025 Value $	Q2 2025 Value $	Value Diff $	Value Chg %

Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).

Quarterly Holders Trend

Quarterly Value Trend

Quarterly Shares Trend

* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.